EQUITY.GURU: Ventripoint Diagnostics (VPT.V) CEO George Adams

Anyone who has had made it through the massively long waiting list for an MRI knows how trying the experience is with the noise, confinement and having to stay still for hours. Ventripoint Diagnostics (VPT.V), a leading cardiological device developer, has brought forward proprietary technologies which would allow physicians to sidestep the traditional MRI when diagnosing heart conditions by using much simpler and cheaper 3D sound imaging to produce much of the same results as a MRI. If the company is able to continue following through on its milestones, Ventripoint could quite possible disrupt a global cardiac monitoring & CRM market predicted to be worth $26.7 billion by 2020.